SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced financial results for the three and six months ended June 30, 2011 and provided an update on key programs. “We are very pleased with the significant developments at Ligand over the past few months and are building strong operating and financial momentum as we move into the second half of 2011,” said John Higgins, President and Chief Executive Officer of Ligand. “Our premier partner GlaxoSmithKline (GSK) recently announced positive Phase III results for one of their pivotal trials for Promacta® in patients with hepatitis C. In addition to recent bullish remarks from GSK’s CEO about this program, we are also pleased to see a significant 47% increase in second quarter sales of Promacta as compared to the first quarter.”
